Genetic Link Between Weight-Loss Drugs and Hair Loss

Weight-Loss Drugs and Hair Loss Risk

A recent study by NYU Langone Health suggests popular weight-loss medications may increase the risk of hair loss in men genetically predisposed to male-pattern baldness. Research indicates that GLP-1 medications like Ozempic, Wegovy, and Zepbound could be linked to a heightened risk of hair loss.

The study, published in the Journal of Investigative Dermatology on September 3, presents the first genetic evidence connecting GLP-1 activity to androgenetic alopecia, a common form of hair loss in men.

Possible Explanations for Hair Loss

Dr. Ahmed El Muntasar, a General Practitioner not involved in the study, offered insights to Newsweek on potential reasons behind the link. El Muntasar explained that rapid weight loss, along with reduced calorie and protein intake and deficiencies in nutrients such as iron, may induce temporary hair shedding. Additionally, GLP-1 receptor activity could contribute to hair loss in individuals already predisposed genetically to male-pattern baldness.

The Centers for Disease Control and Prevention reported that over one-quarter of adults diagnosed with diabetes used GLP-1 injectable medications in 2024, with usage rates being similar among men (25.9 percent) and women (27.2 percent).

Research Findings

Study senior investigator Lynn Petukhova, from the NYU Grossman School of Medicine, highlighted the significance of their findings as they uncover the genetic link between GLP-1 medication use and increased risk for male-pattern hair loss due to androgenetic alopecia. The research identified a 7 percent elevated risk of hair loss, emphasizing a biological connection.

The study focused on the GLP1R gene, which plays a role in increasing GLP-1 receptor protein levels in the body. Researchers compared genetic markers related to increased GLP-1 activity with those associated with androgenetic alopecia — a condition causing hair loss along scalp areas like the top and front.

Beyond Weight Loss

Hair thinning has often been reported by individuals using GLP-1 medications, with scientists attributing this effect to rapid weight loss. When weight stabilizes, hair growth typically resumes. However, researchers suggest a biological basis beyond merely weight loss.

To support their theory, researchers adjusted their analysis to account for other factors affecting hair growth such as hypertension, insulin resistance, and decreased testosterone. Even after adjustments, the risk remained 7 percent. Analyzing genetic data from over 31,000 men and women in the eQTLGen database and more than 205,000 men from another database revealed overlapping genetic signals related to both GLP-1 activity and androgenetic alopecia.

Implications for Patients

Petukhova suggests the new findings could pave the way for screening men and possibly women for their risk of hair loss before prescribing GLP-1 medications. El Muntasar advises against hasty treatment discontinuation or panic, pointing out the modest 7 percent increase and the type of research methods employed.

Research involved genetic data analysis rather than observational studies of patients using medications like semaglutide or tirzepatide. This offers a biological signal rather than confirmation that weight-loss injections directly cause baldness.

Petukhova suggests potential preventative strategies by administering drugs that mitigate hair loss alongside GLP-1 therapies. Further investigation is essential to understand GLP-1 pathways and their impact on hair follicles, including potential gender differences.

Androgenetic alopecia impacts around half of white American men over age 50. As the popularity of GLP-1 drugs rises, understanding side effects and identifying those most vulnerable becomes crucial.